Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
Advanced high-grade serous (HGSC) ovarian cancer is treated with either primary surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval surgery. The decision to proceed with surgery primarily or after chemotherapy is based on a surgeon’s clinical assessment and prediction o...
Main Authors: | Nicholas Cardillo, Eric J. Devor, Silvana Pedra Nobre, Andreea Newtson, Kimberly Leslie, David P. Bender, Brian J. Smith, Michael J. Goodheart, Jesus Gonzalez-Bosquet |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/14/3554 |
Similar Items
-
Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
by: Andreea Newtson, et al.
Published: (2021-04-01) -
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01) -
Immunoexpression of p53 and p16 in Low and High-grade Serous Ovarian Cancer: A Cross-sectional Study
by: Ranajit Mandal, et al.
Published: (2023-11-01) -
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers
by: Paolo Di Lorenzo, et al.
Published: (2022-09-01) -
Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome
by: Jesus Gonzalez-Bosquet, et al.
Published: (2021-03-01)